First Bank & Trust Has $1.76 Million Position in Pfizer Inc. (NYSE:PFE)

First Bank & Trust cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,415 shares of the biopharmaceutical company's stock after selling 11,280 shares during the period. First Bank & Trust's holdings in Pfizer were worth $1,762,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Swiss National Bank boosted its holdings in shares of Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after buying an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the period. Empowered Funds LLC grew its position in shares of Pfizer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after purchasing an additional 227,349 shares during the last quarter. Addison Advisors LLC increased its stake in shares of Pfizer by 394.2% in the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after purchasing an additional 41,668 shares during the period. Finally, KBC Group NV lifted its position in shares of Pfizer by 26.0% during the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock worth $89,872,000 after purchasing an additional 639,985 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

Pfizer Trading Up 1.6 %

Shares of PFE traded up $0.42 on Friday, reaching $26.32. 45,181,154 shares of the company's stock were exchanged, compared to its average volume of 38,114,637. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The business has a 50 day moving average price of $26.28 and a two-hundred day moving average price of $27.44. The stock has a market capitalization of $149.14 billion, a P/E ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is currently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.